HDAC inhibitor confers radiosensitivity to prostate stem-like cells.

Frame, F M; Pellacani, D; Collins, A T; Simms, M S; Mann, V M; Jones, G D D; Meuth, M; Bristow, R G; Maitland, N J

Frame, F M; Pellacani, D; Collins, A T; Simms, M S; Mann, V M; Jones, G D D; Meuth, M; Bristow, R G; Maitland, N J.

Affiliation

Frame FM; YCR Cancer Research Unit, Department of Biology, University of York, Heslington, North Yorkshire, YO10 5DD, UK.

Br J Cancer ; 109(12): 3023-33, 2013 Dec 10.

Article in En | MEDLINE | ID: mdl-24220693

Subject(s)

Histone Deacetylase Inhibitors/pharmacology; Hydroxamic Acids/pharmacology; Neoplastic Stem Cells/drug effects; Neoplastic Stem Cells/pathology; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/radiotherapy; Radiation-Sensitizing Agents/pharmacology; Aged; Aged, 80 and over; Cell Differentiation/drug effects; Cell Differentiation/radiation effects; Comet Assay; DNA Damage; Humans; Male; Middle Aged; Neoplastic Stem Cells/radiation effects; Prostatic Hyperplasia/pathology; Prostatic Neoplasms/genetics; Prostatic Neoplasms/pathology; Tumor Cells, Cultured

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Radiation-Sensitizing Agents / Neoplastic Stem Cells / Histone Deacetylase Inhibitors / Hydroxamic Acids Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2013 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google